{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:41:05Z","timestamp":1790905265331,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jns-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.jns.2018.10.018","type":"journal-article","created":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T02:37:52Z","timestamp":1540003072000},"page":"8-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Predictive score for oral corticosteroid-induced initial worsening of seropositive generalized myasthenia gravis"],"prefix":"10.1016","volume":"396","author":[{"given":"Tetsuya","family":"Kanai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyuki","family":"Uzawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiko","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Himuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kuwabara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2018.10.018_bb0005","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2018.10.018_bb0010","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1177\/1756285608093888","article-title":"Progress in the treatment of myasthenia gravis","volume":"1","author":"Gold","year":"2008","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.jns.2018.10.018_bb0015","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0140-6736(72)90520-X","article-title":"Treatment of myasthenia gravis with prednisone","volume":"1","author":"Jenkins","year":"1972","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2018.10.018_bb0020","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1212\/WNL.22.6.603","article-title":"Corticosteroids in management of severe, generalized myasthenia gravis. Effectiveness and comparison with corticotropin therapy","volume":"22","author":"Brunner","year":"1972","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2018.10.018_bb0025","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1056\/NEJM197401102900204","article-title":"Gradually increasing doses of prednisone in myasthenia gravis. Reducing the hazards of treatment","volume":"290","author":"Seybold","year":"1974","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2018.10.018_bb0030","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1212\/WNL.26.8.729","article-title":"Long-term administration of corticosteroids in myasthenia gravis","volume":"26","author":"Mann","year":"1976","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2018.10.018_bb0035","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jocn.2005.12.041","article-title":"Clinical predictors of steroid-induced exacerbation in myasthenia gravis","volume":"13","author":"Bae","year":"2006","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.jns.2018.10.018_bb0040","first-page":"29","article-title":"A clinical study on crisis in myasthenia gravis","volume":"2","author":"Chung","year":"1984","journal-title":"J. Korean Neurol. Assoc."},{"key":"10.1016\/j.jns.2018.10.018_bb0045","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2018.10.018_bb0050","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1109\/TAC.1974.1100705","article-title":"A new look at the statistical model identification","volume":"19","author":"Akaike","year":"1974","journal-title":"IEEE Trans. Autom. Control"},{"key":"10.1016\/j.jns.2018.10.018_bb0055","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/CND.0000000000000156","article-title":"Outcome measures in Myasthenia Gravis: incorporation into clinical practice","volume":"18","author":"Muppidi","year":"2017","journal-title":"J. Clin. Neuromuscul. Dis."},{"key":"10.1016\/j.jns.2018.10.018_bb0060","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000116785","article-title":"Long-term results of corticosteroid therapy in patients with myasthenia gravis","volume":"32","author":"Evoli","year":"1992","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.jns.2018.10.018_bb0065","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ana.410150316","article-title":"Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients","volume":"15","author":"Pascuzzi","year":"1984","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2018.10.018_bb0070","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1212\/WNL.24.11.1091","article-title":"Corticosteroids: a direct effect at the neuromuscular junction","volume":"24","author":"Wilson","year":"1974","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2018.10.018_bb0075","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1212\/WNL.36.5.729","article-title":"Prednisone-induced worsening of neuromuscular function in myasthenia gravis","volume":"36","author":"Miller","year":"1986","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2018.10.018_bb0080","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1001\/archneur.1985.04060110031011","article-title":"High-dose intravenous methylprednisolone in myasthenia gravis","volume":"42","author":"Arsura","year":"1985","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2018.10.018_bb0085","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.lungcan.2003.12.010","article-title":"Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report","volume":"44","author":"Kim","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jns.2018.10.018_bb0090","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJMra0904569","article-title":"The tumor lysis syndrome","volume":"364","author":"Howard","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2018.10.018_bb0095","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/00005792-197809000-00002","article-title":"Myasthenia gravis in patients with thymoma, with particular reference to onset after thymectomy","volume":"57","author":"Namba","year":"1978","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jns.2018.10.018_bb0100","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1749-6632.1998.tb09571.x","article-title":"A positive role for thymus-derived steroids in formation of the T-cell repertoire","volume":"840","author":"Vacchio","year":"1998","journal-title":"Ann. N. Y. Acad. Sci."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X18304283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X18304283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T08:49:14Z","timestamp":1566463754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X18304283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":20,"alternative-id":["S0022510X18304283"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2018.10.018","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictive score for oral corticosteroid-induced initial worsening of seropositive generalized myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2018.10.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}